Evozyne, founded in 2019, is an artificial intelligence and biotechnology company that uses generative AI models with the goal of creating advanced therapeutic proteins and pharmaceuticals. The company’s platform was built on an AI model called ProT-VAE that was trained by AI hardware company Nvidia, and it is designed to read sequences on amino acids with the goal of enabling it to understand how nature assembles proteins. Evozyne is headquartered in Chicago, Illinois.

Register for Details

For more details on financing and valuation for Evozyne, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Evozyne

Forge green plus iconForge green minus icon

What is Evozyne's IPO price?

The IPO price for Evozyne will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Evozyne?

Evozyne is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Evozyne shares pre-IPO?

If you own Evozyne pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Evozyne a publicly traded company?

Evozyne is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

What is Evozyne's funding to date?

Evozyne has raised $109.19MM to date.
Forge green plus iconForge green minus icon

When was Evozyne founded?

Evozyne was founded in 2020.

Who are Evozyne's major investors?

Valor Equity Partners
Fidelity Management and Research Company
Paragon Biosciences

Evozyne Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
9/27/2023 Series B $50MM raised $XXX.XX $XXX.XX
4/9/2021 Series A $59.18MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: May 17, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.